GO:0090331 negative regulation of platelet aggregation: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090331 (negative regulation of platelet aggregation) describes any process that decreases the rate, frequency or extent of platelet-platelet adhesion via adhesion molecules.
• Endogenous negative regulators such as NR4A1, pyruvate kinase M2 (PKM2), semaphorin 3A (SEMA3A), IL-37, miR-126 and PDGF-AA act as brakes on platelet activation and thrombus formation.
• These pathways are attractive antithrombotic targets because they may inhibit thrombosis with less bleeding risk than conventional antiplatelet drugs.
• Key signaling nodes include cAMP/PKA, cGMP/PKG, PKC isoforms, and receptor-mediated feedback loops that blunt integrin αIIbβ3 activation and granule secretion.
• Dysregulation of negative regulation of platelet aggregation contributes to arterial thrombosis, cardiovascular disease and thrombo-inflammatory conditions.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal testing of candidate negative regulators in platelet biology.
Description
Platelet aggregation is the central event in arterial thrombus formation, and its excessive activation underlies myocardial infarction and ischemic stroke. To prevent pathological clotting while preserving hemostasis, platelets are restrained by endogenous negative regulatory pathways that decrease the rate, frequency or extent of aggregation. The Gene Ontology term GO:0090331, negative regulation of platelet aggregation, captures these braking mechanisms at the biological-process level. Understanding this term is essential for researchers seeking safer antithrombotic strategies, because boosting endogenous inhibitors may uncouple thrombosis from bleeding. Recent studies have identified nuclear receptor NR4A1, the metabolic enzyme PKM2, secreted semaphorin 3A, cytokine IL-37, platelet-derived miR-126 and autocrine PDGF-AA as negative modulators of platelet function. These discoveries position GO:0090331 as a fertile area for target discovery and drug development.
negative regulation of platelet aggregation At A Glance
| GO ID | GO:0090331 |
|---|---|
| GO term | negative regulation of platelet aggregation |
| Ontology | biological_process |
| Synonym | platelet disaggregation |
| Definition | Any process that decreases the rate, frequency or extent of platelet aggregation, the adhesion of one platelet to one or more other platelets via adhesion molecules. |
| Major function | Restrains platelet activation, integrin αIIbβ3 outside-in signaling, granule secretion and thrombus growth. |
| Representative regulators | NR4A1, PKM2, SEMA3A, IL-37, miR-126, PDGF-AA, PKC isoforms. |
| Related processes | Platelet activation, platelet degranulation, blood coagulation, thrombus formation. |
| Disease relevance | Arterial thrombosis, cardiovascular disease, thrombo-inflammation. |
What Is GO:0090331?
GO:0090331 (negative regulation of platelet aggregation) is a biological process defined as any process that decreases the rate, frequency or extent of platelet aggregation, where platelet aggregation is the adhesion of one platelet to one or more other platelets via adhesion molecules. The synonym platelet disaggregation reflects the outcome of these inhibitory pathways. In practice, this term encompasses receptor-mediated signaling, second-messenger cascades, and secreted or intracellular factors that suppress integrin αIIbβ3 activation, granule release, and thrombus growth.
Why Is negative regulation of platelet aggregation Important in Cell Biology?
Negative regulation of platelet aggregation is important because it provides endogenous brakes that prevent excessive thrombus formation while preserving hemostasis. Loss or dysfunction of these pathways promotes arterial thrombosis, and pharmacological amplification of these brakes represents a promising strategy for safer antiplatelet therapy.
• Provides endogenous protection against arterial thrombosis and ischemic cardiovascular events.
• Offers antithrombotic targets that may carry lower bleeding risk than conventional antiplatelet drugs.
• Controls integrin αIIbβ3 activation and outside-in signaling, the final common pathway of aggregation.
• Regulates platelet granule secretion and thrombo-inflammatory mediator release.
• Links metabolic enzymes such as PKM2 to platelet function and thrombosis.
• Involves nuclear receptors such as NR4A1, expanding the repertoire of platelet regulatory mechanisms.
• Includes secreted factors such as SEMA3A and IL-37 that act in autocrine or paracrine loops.
• Is modulated by platelet-derived microRNAs such as miR-126.
• Involves autocrine PDGF-AA feedback via the PDGF alpha-receptor.
• PKC isoforms fine-tune the balance between activation and inhibition in thrombus formation.
What Happens During negative regulation of platelet aggregation?
Receptor-mediated inhibitory signaling
In simple terms: Braking signals start when inhibitory receptors on the platelet surface are engaged.
Negative regulation of platelet aggregation begins with engagement of receptors that dampen activating signals. NR4A1 acts as a novel regulator of platelet activation and thrombus formation, limiting excessive platelet responses. The secreted cell-repulsive protein semaphorin 3A negatively regulates platelet function through receptor-mediated signaling. IL-37 attenuates platelet activation and thrombosis via the IL-1R8 pathway, providing a cytokine-driven brake. Autocrine activation of the platelet-derived growth factor alpha-receptor establishes negative feedback regulation of human platelets.
Second-messenger and kinase cascades
In simple terms: Inside the platelet, chemical messengers and enzymes relay the stop signal.
Intracellular second messengers and kinases transduce inhibitory cues. The metabolic enzyme pyruvate kinase M2 (PKM2) regulates platelet function and arterial thrombosis, linking glycolysis to suppression of aggregation. PKC isoforms participate in thrombus formation and can restrain platelet reactivity. Intraplatelet miR-126 regulates thrombosis, and its reduction contributes to platelet inhibition, indicating microRNA-dependent control of aggregation.
Suppression of integrin αIIbβ3 and granule release
In simple terms: The final step is blocking the glue that makes platelets stick together.
Inhibitory pathways converge on integrin αIIbβ3 and granule secretion. NR4A1 limits platelet activation and thrombus formation, thereby reducing αIIbβ3-dependent aggregation. PKM2 deficiency or modulation alters platelet function and arterial thrombosis, reflecting control of the aggregation machinery. SEMA3A negatively regulates platelet function, blunting adhesion and aggregation responses. IL-37 attenuates platelet activation and thrombosis through IL-1R8, reducing granule release and aggregation.
Feedback loops and resolution of aggregation
In simple terms: Once aggregation starts, feedback loops put the brakes on to prevent runaway clotting.
Autocrine and paracrine feedback loops terminate or limit aggregation. PDGF-AA released by platelets activates the platelet-derived growth factor alpha-receptor to provide negative feedback. miR-126 within platelets regulates thrombosis, and its reduction contributes to platelet inhibition. PKC isoforms modulate thrombus formation, balancing activation and inhibition. These loops collectively define the platelet disaggregation synonym of GO:0090331.
Key Genes Involved in GO:0090331 negative regulation of platelet aggregation
The following genes and proteins have been experimentally implicated in negative regulation of platelet aggregation (GO:0090331).
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR4A1 | Nuclear receptor that limits platelet activation and thrombus formation | Novel regulator of platelet activation and thrombosis |
| PKM2 | Metabolic enzyme regulating platelet function and arterial thrombosis | Links glycolysis to suppression of aggregation |
| SEMA3A | Secreted cell-repulsive protein that negatively regulates platelet function | Endogenous inhibitor of platelet adhesion and aggregation |
| IL37 | Cytokine that attenuates platelet activation and thrombosis via IL-1R8 | Anti-inflammatory brake on platelet activation |
| MIR126 | Intraplatelet microRNA regulating thrombosis | Reduction contributes to platelet inhibition |
| PDGFA | Platelet-derived growth factor A, autocrine negative feedback ligand | Activates PDGF alpha-receptor to restrain platelets |
| PDGFRA | Receptor mediating autocrine negative feedback in platelets | Negative feedback regulation of human platelets |
| PRKCA | PKC isoform involved in thrombus formation | Fine-tunes activation and inhibition |
| PRKCB | PKC isoform involved in thrombus formation | Modulates platelet reactivity |
| PRKCD | PKC isoform involved in thrombus formation | Contributes to regulation of thrombus formation |
| ITGA2B | Integrin αIIb subunit, target of inhibitory signaling | Final common pathway of aggregation |
| ITGB3 | Integrin β3 subunit, target of inhibitory signaling | Final common pathway of aggregation |
| IL1R8 | Receptor mediating IL-37 inhibitory signaling | Pathway for IL-37 attenuation of platelet activation |
| VEGFA | Angiogenic factor with platelet-related functions | Discussed among endogenous modulators |
| SERPINE1 | PAI-1, modulator of thrombosis | Discussed among endogenous modulators |
| ADAMTS13 | von Willebrand factor cleaving protease | Modulates platelet adhesion and aggregation |
| PROCR | Protein C receptor, anticoagulant pathway | Endogenous negative modulator context |
How Is negative regulation of platelet aggregation Regulated?
Negative regulation of platelet aggregation is itself regulated by multiple layers of control. Nuclear receptor NR4A1 acts as a novel regulator of platelet activation and thrombus formation, indicating transcriptional and non-genomic control. The metabolic enzyme PKM2 regulates platelet function and arterial thrombosis, linking cellular metabolism to inhibitory signaling. Secreted factors such as SEMA3A and IL-37 provide autocrine or paracrine inhibition through specific receptors. Intraplatelet miR-126 regulates thrombosis, and its reduction contributes to platelet inhibition, showing microRNA-level control. Autocrine PDGF-AA feedback via the PDGF alpha-receptor establishes negative feedback regulation of human platelets. PKC isoforms further modulate thrombus formation, balancing activating and inhibitory inputs.
negative regulation of platelet aggregation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NR4A1 | Arterial thrombosis, cardiovascular disease | Platelet-specific knockout and overexpression models |
| PKM2 | Arterial thrombosis, metabolic platelet dysfunction | Knockout and point-mutation models |
| SEMA3A | Thrombo-inflammation, platelet hyperactivity | Knockout and recombinant protein treatment models |
| IL37 | Thrombo-inflammatory disease | Knockout and IL-1R8 pathway knock-in models |
| MIR126 | Thrombosis, platelet inhibition | miR-126 knockout and mimic/inhibitor models |
Arterial thrombosis and cardiovascular disease
Loss or impairment of negative regulation of platelet aggregation promotes arterial thrombosis. NR4A1 limits platelet activation and thrombus formation, and its dysfunction may enhance thrombotic risk. PKM2 regulates platelet function and arterial thrombosis, linking metabolic dysregulation to cardiovascular events. Endogenous negative modulators of platelet function are considered potential anti-thrombotic targets. IL-37 attenuates platelet activation and thrombosis through IL-1R8, suggesting that reduced IL-37 signaling may worsen thrombo-inflammatory disease.
Thrombo-inflammation
Platelets contribute to inflammation, and negative regulators such as IL-37 dampen both platelet activation and thrombosis via IL-1R8. SEMA3A negatively regulates platelet function, and its loss may amplify thrombo-inflammatory responses. miR-126 within platelets regulates thrombosis, and its reduction contributes to platelet inhibition, implicating microRNA dysregulation in thrombo-inflammatory conditions.
Bleeding disorders and hemostatic balance
Because negative regulation of platelet aggregation restrains clot formation, excessive activity of these pathways could impair hemostasis. Autocrine PDGF-AA feedback via the PDGF alpha-receptor negatively regulates human platelets, and its overactivity might reduce platelet reactivity. PKC isoforms modulate thrombus formation, and their perturbation can alter the balance between bleeding and clotting. Targeting these pathways for antithrombotic therapy requires careful evaluation of bleeding risk.
From negative regulation of platelet aggregation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is NR4A1 causally required for limiting platelet aggregation? | Platelet-specific NR4A1 knockout |
| Does PKM2 enzymatic activity control arterial thrombosis? | PKM2 point-mutation and knockout models |
| Can SEMA3A supplementation suppress platelet function? | SEMA3A overexpression and recombinant protein models |
| Does IL-37 signaling via IL-1R8 attenuate thrombosis? | IL-37 knockout and IL-1R8 knock-in models |
| How does miR-126 dosage affect platelet inhibition? | miR-126 knockout and transgenic overexpression |
| Does autocrine PDGF-AA feedback require PDGFRA? | PDGFRA knockout and tagged knock-in models |
How to Study the negative regulation of platelet aggregation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Light transmission aggregometry | Rate and extent of platelet aggregation | Testing negative regulators such as NR4A1 and PKM2 |
| Flow cytometry (PAC-1) | Integrin αIIbβ3 activation | Assessing IL-37 and NR4A1 effects |
| FeCl3 thrombosis model | Arterial thrombus formation in vivo | Evaluating PKM2 and IL-37 |
| miRNA profiling | Expression of platelet microRNAs | Studying miR-126 regulation |
| Proteomics | Protein phosphorylation and signaling changes | Mapping PKC and PDGFRA pathways |
| Recombinant protein treatment | Effect of secreted factors on platelets | Testing SEMA3A and IL-37 |
| Platelet-specific knockout | Causal role of a gene in aggregation | NR4A1 and PKM2 studies |
| Autocrine feedback assays | PDGF-AA release and receptor activation | PDGFRA feedback studies |
Platelet aggregometry and functional assays
Light transmission aggregometry and impedance aggregometry measure the rate and extent of platelet aggregation, directly reporting GO:0090331 activity. These assays are used to test whether NR4A1, PKM2, SEMA3A, IL-37, miR-126 or PDGF-AA modulate platelet responses.
Flow cytometry and integrin activation
Flow cytometry with PAC-1 or fibrinogen binding detects activated integrin αIIbβ3, the final common pathway suppressed by negative regulators. This method is applied to assess NR4A1, PKM2 and IL-37 effects on platelet activation.
Thrombosis models in vivo
Arterial thrombosis models such as FeCl3-induced injury or laser-induced thrombus formation evaluate the impact of candidate genes on thrombus growth. NR4A1, PKM2 and IL-37 have been studied in such models.
Molecular and omics profiling
RNA-seq, miRNA profiling and proteomics identify signaling changes downstream of negative regulators. miR-126 profiling and PKM2 metabolic studies exemplify these approaches.
How CRISPR Can Be Used to Study GO:0090331 negative regulation of platelet aggregation
Knockout
CRISPR knockout of candidate genes such as NR4A1, PKM2, SEMA3A, IL37 or MIR126 in megakaryocytic cell lines or primary platelets enables loss-of-function testing of negative regulation of platelet aggregation.
Point Mutation
Point mutations can dissect catalytic or binding residues, for example in PKM2 enzymatic domains or PDGFRA kinase domains, to determine which activities mediate negative regulation of platelet aggregation.
Knock-in
Knock-in of tagged or reporter alleles, such as tagged PDGFRA or IL1R8, allows tracking of receptor localization and signaling during platelet inhibition.
Overexpression
Overexpression of SEMA3A, IL-37 or miR-126 mimics can amplify inhibitory pathways and test whether boosting negative regulation reduces thrombosis.
How EDITGENE Supports negative regulation of platelet aggregation Research
Researchers studying negative regulation of platelet aggregation-related genes often need to determine whether a candidate gene is causally involved in restraining platelet activation or is merely a bystander. EDITGENE provides CRISPR-based cell models and screening services to test causality, dissect mechanism and prioritize antithrombotic targets.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of platelet aggregation research.
Frequently Asked Questions About negative regulation of platelet aggregation
What is GO:0090331 negative regulation of platelet aggregation?
GO:0090331 is a biological process term describing any process that decreases the rate, frequency or extent of platelet aggregation, the adhesion of one platelet to one or more other platelets via adhesion molecules.
What genes are involved in negative regulation of platelet aggregation?
Key genes include NR4A1, PKM2, SEMA3A, IL37, MIR126, PDGFA, PDGFRA and PKC isoforms such as PRKCA, PRKCB and PRKCD.
How does NR4A1 regulate platelet aggregation?
NR4A1 acts as a novel regulator of platelet activation and thrombus formation, limiting excessive platelet responses.
What is the role of PKM2 in platelet function?
The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis, linking glycolysis to suppression of aggregation.
How does semaphorin 3A inhibit platelets?
Semaphorin 3A is a secreted cell-repulsive protein that negatively regulates platelet function.
Does IL-37 affect thrombosis?
IL-37 attenuates platelet activation and thrombosis through the IL-1R8 pathway.
What is the role of miR-126 in platelets?
Intraplatelet miR-126 regulates thrombosis, and its reduction contributes to platelet inhibition.
How does PDGF-AA provide negative feedback in platelets?
Autocrine activation of the platelet-derived growth factor alpha-receptor establishes negative feedback regulation of human platelets.
Which PKC isoforms are involved in thrombus formation?
PKC isoforms including PRKCA, PRKCB and PRKCD participate in thrombus formation and modulate platelet reactivity.
Why is negative regulation of platelet aggregation a drug target?
Endogenous negative modulators of platelet function are considered potential anti-thrombotic targets because they may inhibit thrombosis with less bleeding risk.
Conclusion
GO:0090331 negative regulation of platelet aggregation defines the endogenous braking systems that restrain platelet-platelet adhesion and thrombus growth. Key regulators such as NR4A1, PKM2, SEMA3A, IL-37, miR-126 and PDGF-AA provide mechanistically diverse entry points for antithrombotic discovery. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with aggregometry, flow cytometry and in vivo thrombosis assays, enable rigorous causal testing of these pathways. Targeting negative regulation of platelet aggregation holds promise for safer therapies that uncouple thrombosis from bleeding.
References
- 1. Liu W et al.. 2025. NR4A1 Acts as a Novel Regulator of Platelet Activation and Thrombus Formation.. Circ Res 136(8):809-826 PMID: 40035146
- 2. Nayak MK et al.. 2021. The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis.. Blood 137(12):1658-1668 PMID: 33027814
- 3. Kashiwagi H et al.. 2005. Negative regulation of platelet function by a secreted cell repulsive protein, semaphorin 3A.. Blood 106(3):913-21 PMID: 15831706
- 4. Li YJ et al.. 2017. Novel endogenous negative modulators of platelet function as potential anti-thrombotic targets.. Eur Rev Med Pharmacol Sci 21(13):3146-3158 PMID: 28742189
- 5. Chen Y et al.. 2023. IL-37 Attenuates Platelet Activation and Thrombosis Through IL-1R8 Pathway.. Circ Res 132(9):e134-e150 PMID: 36999436
- 6. Zhang LJ et al.. 2024. Intraplatelet miRNA-126 regulates thrombosis and its reduction contributes to platelet inhibition.. Cardiovasc Res 120(13):1622-1635 PMID: 38900927
- 7. Vassbotn FS et al.. 1994. Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor alpha-receptor.. J Biol Chem 269(19):13874-9 PMID: 8188664
- 8. Zaid Y et al.. 2015. PKCs in thrombus formation.. Pathol Biol (Paris) 63(6):268-71 PMID: 26476932
